Head-to head comparison of anterior nares and nasopharyngeal swabs for SARS-CoV-2

antigen detection in a community drive-through test centre in the UK

Ana I Cubas Atienzar[1*], Rachel L Byrne[1], Ghaith Aljayyoussi[1], Konstantina Kontogianni[1], Daisy

Bengey[1], Karina Clerkin[1], Mathew McIntyre[1], Jahanara Wardale[1], Christopher T Williams[1],

CONDOR steering group, Richard Body[2], Camille Escadafal[3], Emily R Adams[1,4].

[1] Liverpool School of Tropical Medicine, Centre for Drugs and Diagnostics, Liverpool, UK

[2] Manchester University NHS Foundation Trust, UK

[3] FIND, Geneva, Switzerland

[4] Global Access Diagnostics, Bedfordshire, UK

* Corresponding author Ana I Cubas Atienzar Ana.CubasAtienzar@lstmed.ac.uk

Running title: Anterior nares or NP swabs for SARS-CoV-2 RDTs

Corresponding authors: Ana I Cubas Atienzar, Liverpool School of Tropical Medicine, Centre

for Drugs and Diagnostics, Liverpool, UK. Ana.cubasatienzar@lstmed.ac.uk

+44 (0) 151 705 3187

Keywords: SARS-CoV-2, COVID-19, Nasal swabs, nasopharyngeal swabs, antigen detection,

RDT, LFA, head-to-head comparison.

Abstract:

Objective: To conduct a head-to-head diagnostic accuracy evaluation of professionally taken

anterior nares (AN) and nasopharyngeal (NP) swabs for SARS-CoV-2 antigen detection using

rapid diagnostic tests (Ag-RDT).

Methods: NP swabs for SARS-CoV-2 reverse transcription quantitative polymerase chain

reaction (RT-qPCR) testing and paired AN and NP swabs for the antigen detection were

collected from symptomatic participants enrolled at a community drive-through COVID-19

test centre in Liverpool. Two Ag-RDT brands were evaluated: Sure-Status (PMC, India) and

Biocredit (RapiGEN, South Korea). The visual read out of the Ag-RDT test band was

quantitative scored and the 50% and 95% limit of detection (LoD) of both Ag-RDT brands using

AN and NP swabs was calculated using a probabilistic logistic regression model.

Results: A total of 604 participants were recruited of which 241 (40.3%) were SARS-CoV-2

positive by RT-qPCR. Sensitivity and specificity of AN swabs was equivalent to the obtained

with NP swabs: 83.2% (75.2-89.4%) and 98.8% (96.5-99.6%) utilising NP swabs and 84.0%

(76.2-90.1%) and 99.2% (97.0-99.8%) with AN swabs for Sure-Status and; 81.2% (73.1-87.7%)

and 99.0% (94.7-86.5%) with NP swabs and 79.5% (71.3-86.3%) and 100% (96.5-100%) with

AN swabs for Biocredit. The agreement of the AN and NP swabs was high for both brands with

an inter-rater relatability (κ) of 0.918 and 0.833 for Sure-Status and Biocredit, respectively.

The overall 50% LoD and 95% LoD was 0.9-2.4 × 10^4 and 3.0-3.2 × 10^8 RNA copies/mL for NP

swabs and 0.3- 1.1 x 10^5 and 0.7-7.9 x 10^7 RNA copies/mL and for AN swabs with no significant

difference on LoD for any of the swabs types or test brands. Quantitative read-out of test line

intensity was more often higher when using NP swabs with significantly higher scores for both

Ag-RDT brands.

Conclusions: the diagnostic accuracy of the two SARS-CoV-2 Ag-RDTs brands evaluated in this

study was equivalent using AN swabs than NP swabs. However, test line intensity was lower

when using AN swabs which could influence negatively the interpretation of the Ag-RDT

results for lay users. Studies on Ag-RDT self-interpretation using AN and NP swabs are needed

to ensure accurate test use in the wider community.

Abstract word count: 345

Introduction

To meet the immense diagnostic demand of the COVID-19 pandemic, the development of rapid diagnostic tests for the detection of SARS-CoV-2 antigens (Ag-RDTs) became a priority [1]. Nasopharyngeal (NP) swabs are considered the standard of care for SARS-CoV-2 detection[2] and thus the majority of Ag-RDT kits are developed for NP swabs exclusively [1]. However, the use of anterior nasal (AN) swabs has been increasing as a less invasive alternative to promote access to testing in the community and facilitate mass testing programmes particularly in the UK [3].

For Ag-RDTs, studies on Ag-RDTs comparing sensitivity on AN swabs and NP swabs are very limited, with only two reported studies performed on the same Ag-RDT brand, Standard-Q (SD Biosensor, Inc., Korea), one study on professional taken swabs [6] and another in self-taken [7]. Sensitivity obtained with AN swabs was comparable (although 3% to 5% lower) than with NP swabs sensitivity but neither of the swab types fulfilled WHO target product profile (TPP) standards in any of the two studies [8]. AN swabs are considered accurate and clinically acceptable alternatives to NP swabs in outpatient settings for SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) testing [4]. However, an in depth metanalysis on SARS-CoV-2 RT-PCR testing found that anterior nares specimens were 12%-18% less sensitive than NP swabs [5].

The aim of this study was to perform a head-to-head evaluation on two World Health Organisation (WHO) approved or under assessment for Emergency Use listing (WHO-EUL) SARS-CoV-2 Ag-RDT brands marketed for AN and NP swabs: Sure-Status COVID-19 Antigen Card Test (Premier Medical Corporation, India) and Biocredit COVID-19 Antigen Test (RapiGEN, South Korea) respectively. This study is of particular interest in the UK as the use

of home Ag-RDTs on AN swabs has been integral to combatting the spread of COVID-19 during

the pandemic [3],as on the 1st of April 2022 free national RT-PCR COVID-19 testing was

suspended, with the purchase of Ag-RDTs using AN-swabs online or in pharmacies the only

approach to access COVID-19 testing in a non-clinical setting.

Methods

Clinical evaluation

This was a prospective evaluation of consecutive participants enrolled at a community

National Health Service (NHS) drive-through COVID-19 test centre located at the Liverpool

John Lennon Airport. Two Ag-RDT brands were evaluated; Sure-Status COVID-19 Antigen Card

Test (Premier Medical Corporation India) and Biocredit COVID-19 Antigen Test (RapiGEN,

South Korea) referred as Sure-Status and Biocredit thereafter. The study progressed until at

least 100 Ag-RDT positives using AN swabs in line with WHOs requirements for evaluation of

alternative sample type [10].

All adults over the age of 18 who attended the drive-through test centre with symptoms of

COVID-19 were asked to participate in the study. The symptoms included fever, cough,

shortness of breath, tight chest, chest pain, runny nose, sore throat, anosmia, ageusia,

headache, vomiting, abdominal pain, diarrhoea, confusion, rush, or tiredness. Participants

were recruited under the Facilitating Accelerated COVID-19 Diagnostics (FALCON) study using

verbal consent. Ethical approval was obtained from the National Research Ethics Service and

the Health Research Authority (IRAS ID:28422, clinical trial ID: NCT04408170).

Swabs were collected following the same process with the NP swab collected first in one

nostril and placed in Universal Transport Media (UTM) (Copan Diagnostics Inc, Italy) for the

reference RT-qPCR test. This was followed by the collection of two swabs to evaluate the Ag-

RDTs, first an NP swab in the other nostril and finally a AN swab in both nostrils following the

manufacturer's instructions for use (IFU). Samples were given a unique identification code

and transported within cooler bags to the Liverpool School of Tropical Medicine (LSTM) where

samples were processed in category level 3 (CL3) containment laboratory upon arrival.

Sure-Status and Biocredit Ag-RDTs were carried out following their instructions for use (IFU).

The protocol for both Ag-RDT was the same when using AN and NP swabs. Results were read

by two operators, blinded to one another and if a discrepant result occurred, a third operator

acted as a tiebreaker. The visual read out of the Ag-RDT test band was scored on a quantitative

scale from 1 (weak positive) - 10 (strong positive). Ag-RDT results were classified as invalid

when the control line was absent.

RNA was extracted using the QIAamp® 96 Virus QIAcube® HT kit (Qiagen, Germany) on the

QIAcube® (Qiagen, Germany) and screened using TaqPath COVID-19 (ThermoFisher, UK) on

the QuantStudio 5™ thermocycler (ThermoFisher, UK), an internal extraction control was

incorporated before the lysis stage, as recommended by the manufacturer. SARS-CoV-2 RT-

qPCR result was considered (1) positive if any two of the three SARS-CoV-2 target genes (N

gene, ORF1ab and S gene) amplified with cycle threshold (Ct) $\leq$ 40, (2) indeterminate if only

one SARS-CoV-2 gene amplified and (3) negative if the internal extraction control amplified

and the SARS-CoV-2 target genes did not. Samples with invalid RT-qPCR results (no

amplification of the internal extraction control) were re-extracted and re-run once. Viral loads

in UTM swabs were measured with a ten-fold serial dilution standard curve of quantified

specific in vitro-transcribed RNA using five replicates for each standard curve point [11].

Statistical Analysis

Sensitivity, specificity, positive predicted value (PPV) and negative predictive values (NPV)

were calculated with 95% confidence intervals (CIs) by comparing the Ag-RDT results to the

RT-qPCR, as the reference standard. Sub-analyses of diagnostic performance were performed

by swab type (AN and NP), Ct-value ranges, onset of symptoms and vaccination status using

nonparametric statistics. The level of agreement between AN and NP swabs was determined

using Cohen's kappa (κ) [10]. The correlation between test line intensity and viral loads were

measured by Person correlation, coefficient (r_P) [12] and to further analyse Ag-RDT

sensitivities, we used logistic regression, with RNA copy numbers of the RT-qPCR NP swab and

swab type (AN and NP) as independent variables and test outcomes as the dependent

variable, yielding detection probabilities for each viral load level. Statistical analyses were

performed using SPSS V.28.0, Epi Info V3.01 and R scripts. Statistical significance was set at *P*

< 0.05.

Results

Participant demographics

A total of 604 participants were recruited for this study, 372 recruited between August and

October 2021 were enrolled for the Sure-Status Ag-RDT evaluation and 232 recruited

between December 2021 and March 2022 were enrolled for the Biocredit Ag-RDT evaluation.

Details of the demographics of the population of study are found in Table 1. Our study

population had a mean age of 43 years (range 18-81, interquartile range [IQR] 33.0-50.0), 348

(58%) were female and 566 were British (94%), with the remaining 36 participants being of

other ethnic groups (n = 14), white background (n = 9), Asian (n = 8), mix white and black

backgrounds (n = 2) and Arab (n = 1). Three hundred and fourteen participants of the 372

enrolled for the Sure-Status evaluation (84.4%) and 217 participants of the 232 recruited for

Biocredit (93.5%) received complete SARS-CoV-2 vaccination (2 doses). Additionally, 143 of

the participants enrolled from December 2021 (61.6%) for the Biocredit evaluation received

a third dose as part of the UK booster roll out [13]. All participants were symptomatic with a

median onset of symptoms of 2 days (IQR 1-3). The most common symptoms were cough

(387, 64.3%), sore throat (232, 38.5%), headache (203, 33.7%), fever (160, 26.6%), body aches

(80, 13.3%) and runny nose (80, 13.3%) (Table 1).

Overall, 241 participants (40.3%, CI95% 36.3-44.4%) were SARS-CoV-2 positive by RT-qPCR, 6

had indeterminate RT-qPCR results and the remaining 355 were negative. Participants with

indeterminate RT-qPCR results were excluded from further analysis.

RT-qPCR positivity was significantly higher (p<0.05) among the participants enrolled for the

Biocredit evaluation cohort (53.7%, CI95% 47-60.4%) during December 2021 and March 2022

which coincided with the Omicron wave in the UK [14] than among the participants enrolled

between August and October 2021 (32.1%, CI95% 27.4-37.1%) when Delta was the dominant

SARS-CoV-2 variant.

Diagnostic evaluation

Sure Status

The overall sensitivity and specificity for the Sure-Status Ag-RDT compared to RT-qPCR was

83.2% (CI95% 75.2-89.4%) and 98.8% (CI95% 96.5-99.6%) utilising NP swabs and 84.0% (CI95%

76.2-90.1%) and 99.2% (CI95% 97.0-99.8%) with AN swabs. For individuals with Cts < 25, the

sensitivity was 91.8% (CI95% 84.5-96.4%) and 93.8% (CI95% 87.2-97.7%) for NP and AN-swabs

respectively. Seven Ag-RDTs gave invalid results, one NP swab (0.03%) sample and six AN

swab samples (1.6%). Participants with invalid Ag-RDTs results were excluded from further

analysis. Four SARS-CoV-2 positive cases were detected by NP only (3.4%) and six cases were

detected by AN only (5.0%) but this discrepancy on sensitivity between swab types was not

significant (P = 0.43). The percentage of agreement of NP and AN swab using Sure-Status was

96.7% (95% CI 94.3-98.3%) and inter-rater reliability was almost perfect (κ = 0.918). Inter-

rater reliability was strong for both NP (κ = 0.871) and AN (κ = 0.852) swabs when compared

to RT-qPCR.

Biocredit

For the Biocredit Ag-RDT the sensitivity and specificity were 81.2% (CI95%73.1-87.7%) and

99.0% (CI95%94.7-86.5%) with NP swabs and 79.5% (CI95%71.3-86.3%) and 100%

(CI95%96.5-100%) with AN sampling compared to RT-qPCR. Sensitivity was 92.2% (CI95%84.6-

96.8%) and 95.5% (CI95%89.0-98.8%) using NP and AN swabs among participants with Ct <

25. Ten SARS-CoV-2 positive cases were detected solely by NP (8.2%) and eight cases were

detected only by AN (6.6%) but no significance on sensitivity was observed between NP and

AN swabs for this brand of Ag-RDTs either (P = 0.43). The percentage of agreement of NP and

AN swab for Biocredit was 91.6% (95% CI 87.2-94.9%) and inter-rater reliability was strong (κ

= 0.833). Inter-rater reliability was moderate for both NP (κ = 0.790) and AN (κ = 0.782)

sampling compared to RT-qPCR. Diagnostic accuracy for both Sure-Status and Biocredit is

displayed in Table 2.

Head to head comparison of Sure Status and Biocredit

rWe report nosignificant difference in the diagnostic accuracy among participants with

symptoms irrespective of days since onset, or vaccination status for all Ag-RDTs and swabbing

combination (all P values > 0.05). Both Biocredit and Sure-Status Ag-RDTs using both swab

types had better sensitivities on detecting SARS-CoV-2 antigens on individuals with Ct values

< 25 than >30 (P = 0.029 in NP and P = 0.047 in AN for Sure-Status and P = 0.018 and P = 0.001

for Biocredit).

The RNA copy numbers per mL (RNA copies/mL) of RT-PCR NP swabs was calculated and

statistically higher viral loads were obtained for the Sure-Status cohort than Biocredit (Fig 1)

measured by Kruskal–Wallis (P= 0.006). We determined the 50% and 95% limits of detection

(LoD) for both Ag-RDT and swab types based on a logistic regression model (Fig 2). For Sure-

Status, the RNA copies/mL for 50% LoD and 95% LoD were 2.4×10^4 and 3.16×10^8 for NP

specimen and 3.4×10^4 and 7.94×10^7 for AN swabs. For Biocredit, the RNA copies/mL for

LoD50 and LoD95 were 9.12×10^3 and 3.02×10^8 for NP specimen and 1.12×10^5 and 6.76 x

10^6 for AN swabs. Although the LoD95 was better for AN swabs for both Ag-RDT brands (3.98

for Sure-Status and 44.67 for Biocredit), there was no statistical difference on LODs neither

by swab type and Ag-RDT brand (all P values > 0.05).

Quantitative read-out analysis

Quantitative read-out in paired positive AN and NP was more often higher for the NP (40

instances higher on NP and four higher on AN in Sure-Status; and 35 instances higher on NP

and 12 higher on AN in Biocredit) and gave significantly higher scores for both Ag-RDT, Sure-

Status (P = 0.007) and Biocredit (P = 0.013) (Figure 1) measured by Kruskal–Wallis.

Additionally, test lines scores were analysed by RNA copies/mL and these had a positive

correlation. For Biocredit, strong correlation using AN swabs (r_P = 0.727) but moderate using

NP swabs (r_P = 0.591). For Sure-Status, both swab types had a moderate correlation to viral

loads (NP swab r_P = 0.614 and AN swab r_P = 0.661).

DISCUSSION

This is the first diagnostic clinical evaluation of Sure-Status Ag-RDT and results have shown a

satisfactory performance for both AN and NP swabs fulfilling the sensitivity (≥80%) and

specificity (≥97%) outlined in the target product profile (TPP) WHO standards [8]. For Biocredit

Ag-RDT, there are five studies to date that have evaluated the performance of NP swabs

reporting varied sensitivities from 52% to 85% [15]. In this study we report a higher sensitivity

(81.2% ,CI95%73.1-87.7%) and specificity (99.0% ,CI95%94.7-86.5%) of the Biocredit Ag-RDT

fulfilled the WHO standards using NP swab but underperformed in the sensitivity (79.5%,

CI95% 71.3-86.3%) criteria when using AN.

Results presented here demonstrate that AN swabs are equivalent to NP swabs for SARS-CoV-

2 Ag-RDT testing giving comparable sensitivities, 50% LoD and 95% LoD for both Ag-RDTs

brands evaluated here. Our results supports previous findings where AN and NP swabs were

compared for the Ag-RDT Standard-Q (SD Biosensor, Inc., Korea) in Lesotho [6], but we

reported a higher sensitivity compared to the 67.3% and 70.2% for AN and NP swabs

previously described [6]. Studies on RT-qPCR have found lower sensitivity using AN swabs

compared to NP swabs consistently [5]. However, the difference in sensitivity was only

significant for patients with viral loads < 10^3 copies/mL [16] and this threshold is not relevant

to Ag-RDTs of which the limit of detection ranges between 10^4- 10^8 RNA copies/mL in swabs

[11].

Quantitative assessment of the test line scores showed that test line intensity was

significantly higher on NP swabs than AN swabs. The line intensity is an important component

of home testing as studies have shown fainter lines are more difficult to interpret for a lay

person, likely due to lower signal intensity [17]. In an user experience home based study,

77.1% of the cases that the participants interpreted wrongly as negative being positive, were

weak and moderate positives while only 22.9% were strong positives [17]. The significantly

lower intensity of the AN swab compared to NP swab is likely attributed to the differences of

SARS-CoV-2 viral loads in the respiratory tract. Studies have found lower viral loads on AN

swabs compared to NP swabs [16]. Statistical analysis supported this hypothesis where a

positive correlation between viral loads and Ag-RDT test line scores was shownFurther

implementation studies on Ag-RDT test results interpretation by patients or within a home

testing setting are urgently needed to drive self-testing to scale.

This study has several strengths, the use of standardised sampling methods, independent

blinded readers, robust statistical analysis, quantitative assessment of Ag-RDT test line results

and the evaluation of one approved WHO-EUL Ag-RDT test brands (Sure-Status) and under

review (Biocredit). Qualifying it to have high global public health relevance [18].

The main limitation of this study is that the AN swabs were always taken last. The order of

sample collection could have negatively biased the results obtained for AN swabs caused by

a possible sample depletion. However, in the two studies that compared Ag-RDT using AN

swabs, the AN swab was collected first and our reported sensitivity and specificity for AN

swabs are greater than the previous studies [6,7]. Further, studies on RT-qPCR found lower

sensitivity using AN swabs compared to NP swabs [5], even when AN swabs were collected

first [15,18,19]. Thereby it is unlikely that the order of the swabs impacted sample availability

for AN and NP sampling.

In conclusion, this study demonstrates the sensitivity of two SARS-CoV-2 Ag-RDTs using AN-

sampling are comparable to that of NP-sampling. AN-sampling can be performed with less

training, reduces patient discomfort, and enables scaling up of antigen testing strategies.

Test line intensity however is lower when using AN swabs which could influence negatively

the interpretation of the Ag-RDT results. Additional studies on Ag-RDTs using AN swabs on

self-interpretation by a lay person are needed and further education around how to

interpret a positive Ag-RDT to the wider community.

Acknowledgements

The work was funded by the Foundation of Innovative Diagnostics (FIND)

REFERENCES

1   FIND. SARS-CoV-2 diagnostic pipeline. https://www.finddx.org/covid-19/pipeline/

2   Center of Disease Control and Prevention. Interim Guidelines for Collecting, Handling, and

Testing Clinical Specimens for COVID-19. May 22. 2020.

3   GOV.UK. New campaign urges public to get tested twice a week. Published Online First:

2021.https://www.gov.uk/government/news/new-campaign-urges-public-to-get-tested-

twice-a-week

4   Péré H, Péré H, Péré H, *et al.* Nasal swab sampling for SARS-CoV-2: A convenient alternative

in times of nasopharyngeal swab shortage. J. Clin. Microbiol. 2020. doi:10.1128/JCM.00721-

20

5   Zhou Y, OLeary TJ. Relative sensitivity of anterior nares and nasopharyngeal swabs for initial

detection of SARS-CoV-2 in ambulatory patients: Rapid review and meta-Analysis. PLoS One.

2021. doi:10.1371/journal.pone.0254559

6   Labhardt, Niklaus D González Fernández L, Katende, Bulemba Muhairwe J, Bresser M, *et al.*

Head-to-head comparison of nasal and nasopharyngeal sampling using SARS-CoV-2 rapid

antigen testing in Lesotho. *medRxiv* Published Online First: 2022.

doi:10.1101/2021.12.29.21268505

7   Lindner AK, Nikolai O, Kausch F, *et al.* Head-to-head comparison of SARS-CoV-2 antigen-

detecting rapid test with self-collected anterior nasal swab versus professional-collected

nasopharyngeal swab. *Eur Respir J*

2020;**57**:2003961.http://erj.ersjournals.com/lookup/doi/10.1183/13993003.03961-2020

8   (WHO) WHO, R&D Blue Print WH (HQ). Target product profiles for priority diagnostics to

support response to the COVID-19 pandemic v.1.0. Published Online First:

2020.https://www.who.int/publications/m/item/covid-19-target-product-profiles-for-

priority-diagnostics-to-support-response-to-the-covid-19-pandemic-v.0.1

9   GOV.UK. People with a positive lateral flow test no longer required to take confirmatory PCR

test. Published Online First: 2021.https://www.gov.uk/government/news/people-with-a-

positive-lateral-flow-test-no-longer-required-to-take-confirmatory-pcr-test

10   World Health Organization (WHO). Prequalification Teams D. Instructions and requirements

for Emergency Use Listing (EUL) Submission: In vitro diagnostics detecting SARS-CoV-2 nucleic

acid or antigen.

https://extranet.who.int/pqweb/sites/default/files/documents/220317_PQDx_347_Version6

_NAT-Ag.pdf

11   Cubas-Atienzar, Ana I., Kontogianni K, Edwards T, *et al.* Limit of detection in different

matrices of 19 commercially available rapid antigen tests for the detection of SARS-CoV-2. *Sci*

Rep 2021;**11**:1–8. doi:https://doi.org/10.1038/s41598-021-97489-9

12   Schober P, Schwarte LA. Correlation coefficients: Appropriate use and interpretation. *Anesth*

Analg Published Online First: 2018. doi:10.1213/ANE.0000000000002864

13   GOV.UK. Vaccinations in the UK. Coronavirus UK.

2022.https://coronavirus.data.gov.uk/details/vaccinations

14   Mahase E. Covid-19: Is the UK heading for another omicron wave? *BMJ* 2022;**376**.

doi:https://doi.org/10.1136/bmj.o738

15 Brümmer LE, Katzenschlager S, Gaeddert M, *et al.* Accuracy of novel antigen rapid diagnostics

for SARS-CoV-2: A living systematic review and meta-analysis. PLoS Med. 2021.

doi:10.1371/journal.pmed.1003735

16 Callahan C, Lee R, Lee G, *et al.* Nasal-Swab Testing Misses Patients with Low SARS-CoV-2 Viral

Loads. *medRxiv* 2020.

17 Jing M, Bond R, Robertson LJ, *et al.* User experience of home-based AbC-19 SARS-CoV-2

antibody rapid lateral flow immunoassay test. *Sci Rep* 2022;**12**:1173. doi:10.1038/s41598-

022-05097-y

18 World Health Organization (WHO). Coronavirus disease (COVID-19) Pandemic — Emergency

Use Listing Procedure (EUL) open for IVDs. Prequalification Med. Prod. (IVDs, Med. Vaccines

Immun. Devices, Vector Control. https://extranet.who.int/pqweb/vitro-

diagnostics/coronavirus-disease-covid-19-pandemic-—-emergency-use-listing-procedure-eul-

open

19 Hanson KE, Barker AP, Hillyard DR, *et al.* Self-collected anterior nasal and saliva specimens

versus health care worker-collected nasopharyngeal swabs for the molecular detection of

SARS-CoV-2. *J Clin Microbiol* Published Online First: 2020. doi:10.1128/JCM.01824-20

20 Tu Y-P, Jennings R, Hart B, *et al.* Swabs Collected by Patients or Health Care Workers for

SARS-CoV-2 Testing. *N Engl J Med* Published Online First: 2020. doi:10.1056/nejmc2016321

Figure 1. Boxplot of the SARS-CoV-2 viral load distribution of the RT-qPCR NP swabs used as

reference standard for the participants enrolled for Sure-Status and Biocredit Ag-RDT evaluation.

The whiskers show the maximum and minimum values and the vertical line the median. Asterisks

indicate statistical significance between AN and NP swab types.

Figure 2. Limit of detection analyses of upper-respiratory samples positive by RT-qPCR for Sure-

Status and Biocredit using AN and NP swabs. The log10 RNA copies on the x axis were plotted

against a positive (1.0) or negative (0.0) Ag-RDT result on the y axis. Green (Sure-Status) and purple

(Biocredit) curves show logistic regressions of the viral load on the Ag-RDT result; vertical dashed

lines indicate log10 RNA copies subjected to the test at which 50% and 95% LoD of the samples are

expected positive based on the regression results. No significant differences were observed.

Figure 3. Boxplot of the scores of the test lines for both Ag-RDT Sure-Status and Biocredit using AN

and NP swabs. The whiskers show the maximum and minimum values and the vertical line the

median. Asterisks indicate statistical significance between AN and NP swab types.

Table 1. Demographics of the population of study for Sure-Status and Biocredit cohorts

	Sure-Status	Biocredit	All
Total	372	232	604
Age [mean (min-max), IQR]	43 (18-81), 33-53	43 (18-78), 33-51	43 (18-81), 33-52
Gender [%F, (n/N)] IQR]	57%, (211/372)	59%, (137/232)	58%, (348/602)
Triple vaccinated (n, %)	NA*	143 (61.6%)	143 (23.8%)
Double vaccinated (n, %)	314 (84.4%)	74 (40%)	388 (64.4%)
Partially vaccinated (n, %)	29 (7.8%)	4 (1.7%)	33 (5.5%)
Not vaccinated (n, %)	27 (7.3%)	10 (4.3%)	37 (6.2%)
Vaccination not disclosed (n, %)	2 (0.5)	1 (0.3%)	3 (0.5%)
Days symptoms onset [median (IQR); N]	2 (1-3), 371	2 (1-3), 232	2 (1-3), 601
Days 0-3 (n, %)	304, 81.7%	186, 80.2%	490, 81.1%
Days 4-7 (n, %)	56, 15.1%	41, 17.7%	97, 16.1%
Days 8+ (n, %)	10, 2.7%	5, 2.2%	15, 2.5%
RT-qPCR SARS-CoV-2 Positivity [%, (n/N)]	32.1%, (119/371)	53.7%, (122/227)	40.3% (241/598)
Symptom [total n (%), in RT-qPCR positive n (%)]			
Cough	248 (66.7%), 73 (61.3%)	139 (60.0%), 71 (58.2%)	387 (64.3%), 144 (60.0%)
Sore throat	129 (34.7%), 34 (28.6%)	103 (44.4%), 56 (45.9%)	232 (38.5%), 90 (37.4%)
Headache	123 (33.1%), 57 (47.9%)	80 (34.5%), 45 (36.9%)	203 (33.7%), 102 (42.3%)
Fever	106 (28.5%), 30 (25.2%)	54 (23.3%), 28 (22.9%)	160 (26.6%), 58 (24.1%)
Body aches	41 (11.0%), 21 (17.7%)	39 (16.8%), 29 (23.8%)	80 (13.3%), 51 (21.2%)
Runny nose	39 (13.2%), 20 (16.8%)	41 (17.7%), 31 (25.4%)	80 (13.3%), 51 (21.2%)
Loss taste	48 (12.9%), 19 (16.0%)	19 (8.2%), 10 (8.2%)	67 (11.1%), 29 (12.0%)
Loss smell	29 (7.8%), 9 (7.6%)	14 (6.0%), 7 (5.7%)	43 (7.1%), 16 (6.6%)
Chest pain	18 (4.8%),7 (5.9%)	12 (5.2%), 8 (6.6%)	30 (5.0%), 15 (6.2%)
Fatigue	13 (3.5%), 4 (3.4)	17 (7.3%), 10 (8.2%)	30, (5.0%), 14 (5.8%)
Shortness of breath/tight chest	13 (3.5%), 3 (2.5%)	9 (3.9%), 5 (4.1%)	22 (3.6%), 15 (6.2%)
Vomiting	11 (3%), 5 (4.2%)	2 (8.6%), 2 (1.6%)	13 (2.2%), 7 (2.9%)
Diarrhoea	9 (2.4%), 3 (2.5%)	3 (13%), 3 (2.5%)	12 (2.0%), 6 (2.5%)
Abdominal pain	6 (1.6%), 3 (2.5%)	1 (0.4%), 1 (0.8%)	7 (1.2%), 4 (1.7%)
Rash	3 (0.8%), 0 (0.0%)	1 (0.4%), 1 (0.8%)	4 (0.6%), 1 (0.4%)
Confusion	1 (0.3%), 0 (0.0%)	0 (0%)	1 (0.2%), 0 (0%)
Other	159 (42.7%), 68 (57.4%)	134 (57.8%), 85 (69.7%)	293 (48.7%), 153 (63.5%)

*Participants were enrolled before booster rolled out in the UK

372   **Table 2**. Clinical sensitivity and specificity of Sure-Status and Biocredit using NP and Nasal Swab

All Ct values	TP	FP	TN	FN	Sensitivity	Specificity	NPV	PPV
Sure-Status	200	5	494	38	83.9 (78.3-88.1)	99.0 (97.7-99.7)	92.7(90.5-94.4)	97.6 (94.3-98.9)
NP swab	99	2	249	20	83.2 (75.2-89.4)	98.8 (96.5-99.6)	91.7 (88.4-94.2)	97.1 (91.44-99.03)
AN swab	101	2	245	18	84.0 (76.2-90.1)	99.2 (97.0-99.8)	92.8 (89.5-95.1)	98.0 (92.62-99.5)
Biocredit	196	1	209	48	80.3 (74.8-85.1)	99.1 (95.0-99.9)	81.3(77.2-84.9)	99.5 (96.5-100)
NP swab	99	1	104	23	81.2 (73.1-87.7)	99.0 (94.7-86.5)	81.9 (73.99-85.2)	99.0 (93.4-99.9)
AN swab	97	0	105	25	79.5 (71.3-86.3)	100 (96.5-100)	80.8 (74.8-85.6)	100 (100-100)
All NP	198	4	353	43	82.2 (76.7-86.8)	98.9 (97.2-99.7)	89.1 (86.2-91.5)	98.0 (94.9-99.2)
All AN	198	2	350	43	82.2 (76.7-86.8)	99.4 (97.9-99.9)	89.1 (86.2-91.5)	99.0 (96.1-99.8)